Small lymphocytic leukemia, more precisely called small lymphocytic lymphoma (SLL), is a slow-growing cancer of B lymphocytes that is essentially the same disease as chronic lymphocytic leukemia (CLL). The difference is where the cancer cells mainly collect: in SLL they gather in the lymph nodes and spleen, while in CLL they circulate in large numbers in the blood. Many people with SLL need no treatment for years, and when treatment is needed, modern targeted drugs work well for most patients.
Navigating the complexities of small lymphocytic leukemia is mostly about understanding that relationship with CLL, the tests that predict how the disease will behave, and the timing of treatment.
What Is Small Lymphocytic Leukemia?
SLL is a type of non-Hodgkin lymphoma. It arises from mature B cells, the white blood cells that normally make antibodies. The cancerous cells look small and ordinary under the microscope but live far longer than they should, slowly building up in lymph nodes, the spleen, and the bone marrow.
The World Health Organization treats CLL and SLL as one disease with two presentations, so they share the same biology, prognostic tests, and treatments. It sits within the wider group of hematological cancers but behaves very differently from acute leukemias.
SLL vs CLL vs Acute Lymphocytic Leukemia
People often confuse SLL with acute lymphoblastic (lymphocytic) leukemia because the names sound alike. Acute leukemia involves immature cells, progresses quickly, and needs immediate treatment; its outlook depends on a different set of issues, covered in our article on the factors influencing acute lymphocytic leukemia survival rate.
| Feature | SLL | CLL | Acute lymphoblastic leukemia |
|---|---|---|---|
| Cell type | Mature B cells | Mature B cells | Immature lymphoblasts |
| Main site | Lymph nodes, spleen | Blood and marrow | Marrow and blood |
| Monoclonal B cells in blood | Below 5 x 10⁹/L | 5 x 10⁹/L or more | Blasts usually present |
| Pace | Slow | Slow | Rapid |
| Typical age | Older adults | Older adults | Mostly children, also adults |
Causes and Risk Factors
The exact cause is unknown. SLL develops from acquired genetic changes in B cells rather than from anything a person inherits directly. Recognized risk factors include:
- Older age, with most people diagnosed in their sixties or seventies
- Male sex
- A family history of CLL, SLL, or other lymphomas
- Exposure to certain chemicals, including some herbicides and pesticides
Many people have a precursor state called monoclonal B-cell lymphocytosis for years beforehand, a small clonal population that most people never progress from.
Symptoms and Clinical Presentation
SLL is often found by chance, when a doctor notices painless swollen lymph nodes in the neck, armpit, or groin, or when a scan done for another reason shows enlarged nodes or spleen. Other possible features include:
- Fatigue
- A feeling of fullness under the left ribs from an enlarged spleen
- Frequent infections, because the immune system works less effectively
- “B symptoms”: fevers, drenching night sweats, and unintended weight loss
As the disease advances, marrow involvement can lower red cell and platelet counts. SLL can also trigger autoimmune problems, such as the immune system destroying red cells or platelets.
Diagnosis and Testing
SLL is usually diagnosed with a lymph node biopsy, ideally an excisional or core biopsy rather than a fine-needle sample. The cells are tested by flow cytometry or immunohistochemistry, which shows a characteristic pattern: CD5, CD19, and CD23 positive, with weak CD20 and weak surface immunoglobulin. This pattern helps separate SLL from look-alikes such as mantle cell lymphoma.
Further tests help predict behavior and guide therapy:
- FISH testing for chromosome changes such as del(17p), del(11q), trisomy 12, and del(13q)
- TP53 mutation analysis
- IGHV mutation status; unmutated IGHV generally predicts a more active disease course
- Blood counts, kidney and liver tests, and a CT scan to map disease extent
SLL is usually staged with the Lugano system used for lymphomas, while CLL uses the Rai or Binet systems.
Treatment Options
For early, symptom-free disease, the standard approach is active monitoring, often called “watch and wait.” Starting treatment early has not been shown to help people who have no symptoms, and it exposes them to side effects.
Treatment is usually started for bulky or growing lymph nodes, an enlarging spleen, falling blood counts caused by marrow involvement, or troublesome B symptoms. Main options include:
- BTK inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib, taken as daily tablets, typically continued as long as they work
- Venetoclax with obinutuzumab, a fixed-duration course of about one year
- Chemoimmunotherapy such as fludarabine, cyclophosphamide, and rituximab, now used much less often and mainly in selected younger patients with favorable features
People with del(17p) or TP53 mutations respond poorly to chemotherapy and are treated with targeted agents. Localized early-stage SLL may occasionally be treated with radiation alone.
Research continues into combinations of targeted drugs, newer BTK inhibitors for resistant disease, and CAR-T cell therapy. Rarely, SLL transforms into an aggressive lymphoma, called Richter transformation, which needs different treatment.
Living With SLL
Because SLL is usually a long-term condition, day-to-day health habits matter. The disease itself, and some of its treatments, reduce the body’s ability to fight infection, so fevers or chest infections should be reported promptly rather than waited out.
People with SLL also have a higher risk of second cancers, particularly skin cancers, so sun protection and regular skin checks are sensible. Routine age-appropriate cancer screening should continue as usual.
Follow-up visits typically involve a physical examination for enlarged lymph nodes or spleen, plus blood counts. Between visits, keep a note of new lumps, night sweats, or weight loss to discuss with your team.
Key Takeaways
- SLL and CLL are the same disease; SLL mainly involves lymph nodes rather than blood.
- Diagnosis rests on a lymph node biopsy and flow cytometry.
- FISH, TP53, and IGHV testing predict behavior and guide drug choice.
- Many patients are safely monitored for years without treatment.
- Targeted drugs have largely replaced chemotherapy for most patients.
Like other hematologic conditions, SLL is best managed by a hematologist familiar with its long, often gentle course.
Frequently Asked Questions
Is small lymphocytic leukemia curable?
For most people, SLL is considered a chronic, controllable condition rather than a curable one. Many live for many years with good quality of life, and some never need treatment at all.
Why am I not being treated right away?
For symptom-free SLL, early treatment does not improve outcomes and adds side effects. Regular checkups allow your team to start therapy at the point where it clearly helps.
What are the common side effects of BTK inhibitors?
They can include bruising, diarrhea, joint aches, high blood pressure, and irregular heart rhythms such as atrial fibrillation. Newer drugs in this class tend to cause heart rhythm problems less often, and your team will monitor for them.
Should I get vaccinated?
Yes. Because SLL weakens the immune system, inactivated vaccines such as influenza, pneumococcal, and COVID-19 vaccines are recommended. Live vaccines are generally avoided, so check with your hematologist first.
